STOCKS TELEGRAPH

Tag: XTLB

  • Strategic Acquisition Drives XTL Biopharmaceuticals (XTLB) To Nearly Double

    Strategic Acquisition Drives XTL Biopharmaceuticals (XTLB) To Nearly Double

    During the current trading session, the shares of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) are experiencing a notable surge of 98.06%, culminating in a valuation of $2.04. This remarkable upswing in XTLB shares is directly attributable to a recent strategic acquisition move.

    XTL Biopharmaceuticals (XTLB) announced today its formal agreement with THE SOCIAL PROXY Ltd., delineated within a binding term sheet. The Social Proxy stands as an avant-garde entity specializing in web data solutions, crafting and empowering a distinctive ethical, IP-centric proxy and data extraction platform tailored for AI & BI Applications at scale.

    Pursuant to the Term Sheet, XTLB intends to acquire the entirety of Social Proxy’s issued and outstanding share capital on a fully diluted basis. This acquisition will be executed through a private placement, wherein the Company will issue a certain number of ADS’s representing 44.6% of its issued and outstanding share capital post-issuance, alongside a payment of US$430,000 to Social Proxy’s shareholders.

    Furthermore, as a component of the Transaction, Social Proxy’s shareholders will receive additional warrants, exercisable upon meeting specific financial benchmarks within a three-year timeframe subsequent to the Transaction’s closure. As part of XTL Biopharmaceuticals’ overarching strategy, the proposed transaction complements its asset portfolio with high growth prospects.

    A private placement commitment of US$1,500,000 has been obtained by the Company to strengthen its financial position and expedite the transaction. In exchange for their investment, investors will receive 1,500,000 units, each consisting of one ADS and one warrant that can be exercised for five years after issuance at a price of US$1.20 per warrant.

    Due to the involvement of Mr. Alexander Rabinovich, a director and 23.5% shareholder of the company, the investment is subject to shareholder approval. Following the acquisition, Social Proxy will operate as a fully-owned subsidiary of XTL Biopharmaceuticals, and its shareholders will have the authority to select two of the company’s possible seven board of directors representatives.

  • Is this a bubble or reality: XTL Biopharmaceuticals Ltd (XTLB) stock sky-rocketed in the pre-market session?

    Is this a bubble or reality: XTL Biopharmaceuticals Ltd (XTLB) stock sky-rocketed in the pre-market session?

    NASDAQ listed XTL Biopharmaceuticals Ltd ADR (XTLB)was founded in 1993 and became a public company in 2000. It focuses on the acquisition and development of late-stage medication product candidates for the treatment of unmet clinical needs.

    The Company of the Healthcare sector stock surged dramatically more than 170% to $7.82 in the pre-market session despite no publication was released by the company.

    So, what do we want no know about XTL Biopharmaceuticals (XTLB)?

    The XTLbio pipeline mainly emphasizes systematically identifying, validating, and in-licensing therapeutic candidates with advantages over current therapies and which address unmet medical needs. Today 3 compounds are actively being developed, all in clinical stages.

    • hCDR1 is currently undergoing Phase 3 testing at XTL Biopharmaceuticals, and is on the top of their drug development program. New compound hCDR1, acting through an entirely novel mechanism of action, for the management of Systemic Lupus Erythematosus has been generated. Treatment for SLE currently focuses on immune suppressing drugs, such as azathioprine, cyclosporine, corticosteroids and others.

    One of the most important factors to consider here is that the FDA has only approved a single treatment for SLE in the last 50 years; it is Benlysta (belimumab), approved back in the year 2011.

    • Meanwhile, the Company’s another medicine in process of development is Erythropoietin (rHuEPO), which apparently is in phase 2 of its trial. The development of Recombinant Human Erythropoietin (rHuEPO), a known anemic agent, has the aim of prolonging the survival of patients with advanced Multiple Myeloma. rHuEPO was designated an orphan drug by the FDA in 2011 for the treatment of multiple myeloma blood cancer.

    Finally,

    As biotech companies rely on FDA approvals and feedback, investors in the biotech market must be aware of the fact that there can be a long wait when it comes to investment gains.

  • Early Morning Vibes: 4 Top Movers To Watch For Weekend

    Early Morning Vibes: 4 Top Movers To Watch For Weekend

    Investors remain concerned about the situation in the bond markets. Last week, Fed Chairman Jerome Powell was able to calm the markets somewhat, but yesterday his speech went down the wrong way with investors. During his speech, he indicated that the bond market situation has his attention, but he saw no reason to intervene yet.

    Powell also said it is very likely that inflation will rise further as the economy recovers, but he thinks this will only be a temporary effect. Without sustained inflation coupled with a return to full employment, the central bank is unlikely to hike interest rates. His thoughts combined with the lack of measures led to rising interest rates again.

    At the same time, this was again enough reason for investors to hit the sell buttons. Technology was again the bitten dog, the Nasdaq closed 2.11% lower at 12,723 points. The S&P 500 did less badly with a loss of 1.34% to 3,768 points. The same shares as Wednesday were sold off again. For example, we saw Baidu again lose more than 6.2% and Tesla also fell by 4.86%.

    The Nasdaq has fallen below 13,000 points with all the violence through the support surface. The technology fair is now in the red for the current year. In Thursday’s Morning Call I already indicated that the breakthrough of the neckline of the head & shoulder pattern has a price target of approximately 12,000 points.

    Today Top Movers

    Waitr Holdings Inc. (WTRH) stock soared 20.74% to $3.61 in the pre-market trading. The firm recently declared partnership with Flow Payments to create a compliant marketplace, delivery and payment solution for dispensaries selling cannabis.

    Sify Technologies Limited (NASDAQ: SIFY) shares are trading up 38.15% at $3.73 at the time of writing. According to people with knowledge of the matter, Blackstone Group Inc. is in talks to acquire a minority stake in Sify Technologies Ltd.(SIFY), an Indian technology company. Company’s 52-week ranged between $0.56 to $5.89. 

    XTL Biopharmaceuticals Ltd. (XTLB) grew over 159.52% at $7.5 in pre-market trading today.

    CLPS Incorporation (CLPS), a Information Technology Services company, rose about 44.93% at $6.0 in pre-market trading Friday. The company reported today in its unaudited financial results for the six months ended December 31, 2020, that revenues increased by $15.7 million, or 37.0%, to $58.3 million from $42.6 million in the prior year period.

    Top Upgrades & Downgrades

    DZ Bank turned bullish on Exxon Mobil Corporation (XOM), upgrading the stock to “Hold” and assigning a $58 price target. 

    Cisco Systems Inc (CSCO) has won the favor of JPMorgan’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $55, suggesting 23.42% additional upside for the stock. 

    Fifth Third Bancorp (FITB) received an upgrade from analysts at Goldman Sachs, who also set their one-year price target on the stock to $45. They keep their rating on FITB as Buy from Buy in a recently issued research note. 

    Earlier Friday Raymond James reduced its rating on Senseonics Holdings Inc (SENS) stock to Underperform from Market Perform. 

    JPMorgan analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Nikola Corporation has been changed to Neutral from Overweight. 

    Analysts at ICICI Securities downgraded Wipro Limited (WIT)’s stock to Sell from Reduce Friday.

    Latest Insider Activity

    Advanced Micro Devices Inc. (AMD) EVP, CFO & Treasurer KUMAR DEVINDER announced the sale of shares taking place on Mar 02 at $86.09 for some 63,044 shares. The total came to more than $5.43 million. 

    PayPal Holdings Inc. (PYPL) EVP, Chief Bus. Aff. & Legal O Pentland Adele Louise sold on Mar 03 a total of 60,677 shares at $261.21 on average. The insider’s sale generated proceeds of almost $19.66 million. 

    Viatris Inc. (VTRS) Director CORNWELL W DON declared the purchase of shares taking place on Mar 03 at $13.84 for some 3,000 shares. The transaction amount was around $41515.0. 

    Vistra Corp. (VST) Director BARBAS PAUL M bought on Mar 03 a total 67,159 shares at $16.42 on average. The purchase cost the insider an estimated $197,040.

    Important Earnings


    Top US earnings releases scheduled for today include Big Lots Inc. (NYSE:BIG). It will announce its Jan 2021 financial results. The company is expected to report earnings of $2.5 per share from revenues of $1.74B in the three-month period. 

    Analysts expect Hibbett Sports Inc. (NASDAQ:HIBB) to report a net income (adjusted) of $1.37 per share, when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Jan 2021 is predicted to come in at $378.42M.